<div>Data are represented as mean ± SD and median with interquartile range.</div><div>References</div><div>1. Li R, Sun J, Ren LM, Wang HY, Liu WH, Zhang XW, et al. Epidemiology
of eight common rheumatic diseases in China: a large-scale
cross-sectional survey in Beijing. Rheumatology (Oxford, England).
2012;51(4):721-9.</div><div>2. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO,
3rd, et al. 2010 Rheumatoid arthritis classification criteria: an
American College of Rheumatology/European League Against Rheumatism
collaborative initiative. Arthritis and rheumatism. 2010;62(9):2569-81.</div><div>3. Zhao J, Su Y, Li R, Ye H, Zou Q, Fang Y, et al. Classification
criteria of early rheumatoid arthritis and validation of its performance
in a multi-centre cohort. Clin Exp Rheumatol. 2014;32(5):667-73.</div><div>4. Burgers LE, van Steenbergen HW, Ten Brinck RM, Huizinga TW, van der
Helm-van Mil AH. Differences in the symptomatic phase preceding
ACPA-positive and ACPA-negative RA: a longitudinal study in arthralgia
during progression to clinical arthritis. Annals of the rheumatic
diseases. 2017;76(10):1751-4.</div><div>5. Ding B, Padyukov L, Lundstrom E, Seielstad M, Plenge RM, Oksenberg
JR, et al. Different patterns of associations with anti-citrullinated
protein antibody-positive and anti-citrullinated protein
antibody-negative rheumatoid arthritis in the extended major
histocompatibility complex region. Arthritis and rheumatism.
2009;60(1):30-8.</div><div>6. Belakova G, Manka V, Zanova E, Racay P. Benefits of anticitrullinated
peptides examination in rheumatoid arthritis. Nigerian journal of
clinical practice. 2018;21(10):1380-3.</div><div>7. Im CH, Kang EH, Ryu HJ, Lee JH, Lee EY, Lee YJ, et al. Anti-cyclic
citrullinated peptide antibody is associated with radiographic erosion
in rheumatoid arthritis independently of shared epitope status.
Rheumatology international. 2009;29(3):251-6.</div><div>8. Cheng TT, Yu SF, Su FM, Chen YC, Su BY, Chiu WC, et al.
Anti-CCP-positive patients with RA have a higher 10-year probability of
fracture evaluated by FRAX(R): a registry study of RA with
osteoporosis/fracture. Arthritis research &amp; therapy. 2018;20(1):16.</div><div>9. Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, et al.
Additive effect of anti-citrullinated protein antibodies and rheumatoid
factor on bone erosions in patients with RA. Annals of the rheumatic
diseases. 2015;74(12):2151-6.</div><div>10. Schett G. The role of ACPAs in at-risk individuals: Early targeting
of the bone and joints. Best practice &amp; research Clinical rheumatology.
2017;31(1):53-8.</div><div>11. England BR, Thiele GM, Mikuls TR. Anticitrullinated protein
antibodies: origin and role in the pathogenesis of rheumatoid arthritis.
Current opinion in rheumatology. 2017;29(1):57-64.</div><div>12. Padyukov L, Seielstad M, Ong RT, Ding B, Ronnelid J, Seddighzadeh M,
et al. A genome-wide association study suggests contrasting associations
in ACPA-positive versus ACPA-negative rheumatoid arthritis. Annals of
the rheumatic diseases. 2011;70(2):259-65.</div><div>13. Viatte S, Plant D, Bowes J, Lunt M, Eyre S, Barton A, et al. Genetic
markers of rheumatoid arthritis susceptibility in anti-citrullinated
peptide antibody negative patients. Annals of the rheumatic diseases.
2012;71(12):1984-90.</div><div>14. Yarwood A, Huizinga TW, Worthington J. The genetics of rheumatoid
arthritis: risk and protection in different stages of the evolution of
RA. Rheumatology (Oxford, England). 2016;55(2):199-209.</div><div>15. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: an
assessment of technical reproducibility and comparison with gene
expression arrays. Genome research. 2008;18(9):1509-17.</div><div>16. Heruth DP, Gibson M, Grigoryev DN, Zhang LQ, Ye SQ. RNA-seq analysis
of synovial fibroblasts brings new insights into rheumatoid arthritis.
Cell &amp; bioscience. 2012;2(1):43.</div><div>17. Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W,
Iwakura Y, et al. Interleukin-17A upregulates receptor activator of
NF-kappaB on osteoclast precursors. Arthritis research &amp; therapy.
2010;12(1):R29.</div><div>18. Pratt AG, Swan DC, Richardson S, Wilson G, Hilkens CM, Young DA, et
al. A CD4 T cell gene signature for early rheumatoid arthritis
implicates interleukin 6-mediated STAT3 signalling, particularly in
anti-citrullinated peptide antibody-negative disease. Annals of the
rheumatic diseases. 2012;71(8):1374-81.</div><div>19. Wright HL, Cox T, Moots RJ, Edwards SW. Neutrophil biomarkers
predict response to therapy with tumor necrosis factor inhibitors in
rheumatoid arthritis. Journal of leukocyte biology. 2017;101(3):785-95.</div><div>20. Yu F, Duan C, Zhang X, Yao D, Si G, Gao Y, et al. RNA-seq analysis
reveals different gene ontologies and pathways in rheumatoid arthritis
and Kashin-Beck disease. International journal of rheumatic diseases.
2018;21(9):1686-94.</div><div>21. Sumitomo S, Nagafuchi Y, Tsuchida Y, Tsuchiya H, Ota M, Ishigaki K,
et al. Transcriptome analysis of peripheral blood from patients with
rheumatoid arthritis: a systematic review. Inflammation and
regeneration. 2018;38:21.</div><div>22. Wolpe SD, Cerami A. Macrophage inflammatory proteins 1 and 2:
members of a novel superfamily of cytokines. FASEB J.
1989;3(14):2565-73.</div><div>23. De Filippo K, Dudeck A, Hasenberg M, Nye E, van Rooijen N, Hartmann
K, et al. Mast cell and macrophage chemokines CXCL1/CXCL2 control the
early stage of neutrophil recruitment during tissue inflammation. Blood.
2013;121(24):4930-7.</div><div>24. Gang X, Sun Y, Li F, Yu T, Jiang Z, Zhu X, et al. Identification of
key genes associated with rheumatoid arthritis with bioinformatics
approach. Medicine. 2017;96(31):e7673.</div><div>25. Jacobs JP, Ortiz-Lopez A, Campbell JJ, Gerard CJ, Mathis D, Benoist
C. Deficiency of CXCR2, but not other chemokine receptors, attenuates
autoantibody-mediated arthritis in a murine model. Arthritis and
rheumatism. 2010;62(7):1921-32.</div><div>26. Ha J, Choi HS, Lee Y, Kwon HJ, Song YW, Kim HH. CXC chemokine ligand
2 induced by receptor activator of NF-kappa B ligand enhances
osteoclastogenesis. Journal of immunology (Baltimore, Md : 1950).
2010;184(9):4717-24.</div><div>27. Boro M, Balaji KN. CXCL1 and CXCL2 Regulate NLRP3 Inflammasome
Activation via G-Protein-Coupled Receptor CXCR2. Journal of immunology
(Baltimore, Md : 1950). 2017;199(5):1660-71.</div><div>28. Henn D, Abu-Halima M, Wermke D, Falkner F, Thomas B, Kopple C, et
al. MicroRNA-regulated pathways of flow-stimulated angiogenesis and
vascular remodeling in vivo. Journal of translational medicine.
2019;17(1):22.</div><div>29. Subat S, Mogushi K, Yasen M, Kohda T, Ishikawa Y, Tanaka H.
Identification of genes and pathways, including the CXCL2 axis, altered
by DNA methylation in hepatocellular carcinoma. Journal of cancer
research and clinical oncology. 2019;145(3):675-84.</div><div>30. Lu J, Xu W, Qian J, Wang S, Zhang B, Zhang L, et al. Transcriptome
profiling analysis reveals that CXCL2 is involved in anlotinib
resistance in human lung cancer cells. BMC medical genomics.
2019;12(Suppl 2):38.</div><div>31. Ha J, Lee Y, Kim HH. CXCL2 mediates lipopolysaccharide-induced
osteoclastogenesis in RANKL-primed precursors. Cytokine.
2011;55(1):48-55.</div><div>32. Cheng Y, Ma XL, Wei YQ, Wei XW. Potential roles and targeted therapy
of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochim
Biophys Acta Rev Cancer. 2019;1871(2):289-312.</div><div>33. Park JH, Lee NK, Lee SY. Current Understanding of RANK Signaling in
Osteoclast Differentiation and Maturation. Molecules and cells.
2017;40(10):706-13.</div><div>34. Song F, Zhou L, Zhao J, Liu Q, Yang M, Tan R, et al. Eriodictyol
Inhibits RANKL-Induced Osteoclast Formation and Function Via Inhibition
of NFATc1 Activity. Journal of cellular physiology. 2016;231(9):1983-93.</div><div>35. Barsante MM, Cunha TM, Allegretti M, Cattani F, Policani F, Bizzarri
C, et al. Blockade of the chemokine receptor CXCR2 ameliorates
adjuvant-induced arthritis in rats. British journal of pharmacology.
2008;153(5):992-1002.</div><div>36. Min SH, Wang Y, Gonsiorek W, Anilkumar G, Kozlowski J, Lundell D, et
al. Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and
CCR2 in a mouse model of arthritis. Biochemical and biophysical research
communications. 2010;391(1):1080-6.</div><div>37. Kim SJ, Chen Z, Essani AB, Elshabrawy HA, Volin MV, Fantuzzi G, et
al. Differential impact of obesity on the pathogenesis of RA or
preclinical models is contingent on the disease status. Annals of the
rheumatic diseases. 2017;76(4):731-9.</div>